SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer

Although many anticancer drugs have been developed for triple-negative breast cancer (TNBC) treatment, there are no obvious therapies. Moreover, the combination of epidermal growth factor receptor- (EGFR-) targeted therapeutics and classical chemotherapeutic drugs has been assessed in clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yu-Jeong, Lee, Kangwook, Yoon, Ji-Hye, Cho, Sung-Gook, Kim, Yun-Gyeong, Jeong, Miso, Hwang, Hyun-Ha, Lee, Seo Yeon, Jung, Se-Eun, Ko, Seong-Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098291/
https://www.ncbi.nlm.nih.gov/pubmed/35572726
http://dx.doi.org/10.1155/2022/3647900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098291/
https://www.ncbi.nlm.nih.gov/pubmed/35572726
http://dx.doi.org/10.1155/2022/3647900

Ejemplares similares